Project Title: Clinical Trial of the Next Generation Condom
Condoms are the only medical device that simultaneously functions as a contraceptive while also preventing sexually transmitted infections. However, condom avoidance results in more than 120 million unintended pregnancies and more than 365 million sexually transmitted infections each year.
Eudaemon Technologies have developed a world first, superior feeling condom made from tissue-like materials called tough hydrogels. Eudaemon's Hydrogel condoms have the potential to overcome fundamental issues with current condoms, like feel, allergies, odours and tastes while saving healthcare agencies millions of dollars and disrupting a growing USD $9 billion market.
This CTCM project will help Eudaemon commercialise the condom by enabling completion of a pilot clinical trial required as a key step for regulatory compliance. Critically a successful pilot trial will support Eudaemon's expanding Industry 4.0 capabilities in local scaled manufacturing and quality control, ultimately leading to pathways for market entry.
CTCM Project Round: One
- CTCM Grant: $1,500,000
- Industry Contribution: $3,423,000
Duration: November 2022 – October 2024